Literature DB >> 10664443

Cellular and molecular basis of preferential metastasis of breast cancer to bone.

T Yoneda1.   

Abstract

Bone is one of the most preferential target sites for cancer metastasis. Breast cancer has a predilection for spreading to bone, and bone metastasis is one of the major causes of increased morbidity and eventual mortality in breast cancer patients. None of the currently available therapies is effective for curing bone metastases in these patients. Elucidation of the cellular and molecular mechanism by which breast cancer selectively spreads to bone is essential for the development of mechanism-based effective and specific therapeutic interventions for this deleterious complication in breast cancer. Here, two questions are addressed to study the mechanism of breast cancer metastasis to bone: (1) What makes bone a preferential target site of metastasis? (2) What makes breast cancer able to colonize bone? (3) An animal model in which intracardiac inoculation of breast cancer cells selectively causes osteolytic bone metastases was developed. Experimental results obtained using this unique in-vivo model of bone metastasis are described and discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664443     DOI: 10.1007/s007760050012

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  30 in total

Review 1.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Stephanie Corn; Abraham Schneider; Laurie K McCauley
Journal:  Cancer Treat Res       Date:  2004

2.  Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists.

Authors:  Alexandre Chigaev; Yang Wu; D Bart Williams; Yelena Smagley; Larry A Sklar
Journal:  J Biol Chem       Date:  2010-12-03       Impact factor: 5.157

3.  Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.

Authors:  Odete Mendes; Hun-Taek Kim; George Stoica
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model.

Authors:  S M Eck; P J Hoopes; B L Petrella; C I Coon; C E Brinckerhoff
Journal:  Breast Cancer Res Treat       Date:  2008-07-03       Impact factor: 4.872

5.  Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer.

Authors:  Karen M Bussard; Andrea M Mastro
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-12-02       Impact factor: 2.673

Review 6.  Molecular alterations that drive breast cancer metastasis to bone.

Authors:  Penelope D Ottewell; Liam O'Donnell; Ingunn Holen
Journal:  Bonekey Rep       Date:  2015-03-18

7.  RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4.

Authors:  Eliane Shizuka Nakamura; Keiichi Koizumi; Mitsuo Kobayashi; Yurika Saitoh; Yoshihisa Arita; Takashi Nakayama; Hiroaki Sakurai; Osamu Yoshie; Ikuo Saiki
Journal:  Clin Exp Metastasis       Date:  2006-07-05       Impact factor: 5.150

8.  Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis.

Authors:  Didier Dréau; Amel Karaa; Cathy Culberson; Heather Wyan; Iain H McKillop; Mark G Clemens
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

Review 9.  Molecular mechanisms of bone metastasis and associated muscle weakness.

Authors:  David L Waning; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

10.  An in vivo mouse model of intraosseous spinal cancer causing evolving paraplegia.

Authors:  Davina A F Cossigny; Effie Mouhtouris; Sathana Dushyanthen; Augusto Gonzalvo; Gerald M Y Quan
Journal:  J Neurooncol       Date:  2013-08-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.